By Aaron Vehling ( January 8, 2015, 2:31 PM EST) -- Novartis AG and GlaxoSmithKline PLC on Wednesday offered Europe's competition watchdog unspecified fixes on deals worth nearly $23 billion combined, including Novartis' $16 billion acquisition of rival GSK's cancer drugs, giving the regulator assurances that their transactions aren't anti-competitive....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.